Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘Tmunity’

Stacking up the various modalities – what do we find?

It’s time to talk about an particular target in AML because there are now a variety of different modalities involved since we last covered it, which makes it rather more intriguing than most. There’s antibodies, ADCs, CAR-T cell therapies, stem cells, and various bispecifics to name a few such examples.

To be clear, we’re not talking about CD123 here either, but rather an entirely different protein that is receiving increasing attention from multiple companies.

How does the evidence stack up?  Will one particular approach stand out from all the others?

Next, perhaps what makes this post even more interesting is we have an engaging interview with one of the company CEO’s in this niche to share, so we can see how they view things from the lens of looking at things in a different way from many of the other competitors.

To learn more from our oncology coverage and get a heads up on our latest biotech expert interview, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Downtown San Francisco

San Francisco — Amongst all the chaos and frenetic activity that abounds big Pharma at JPM each year, I always look forward to hearing what the smaller biotechs are up to on days 3 and 4, as well as seeing how far some of them have progressed since our previous update on their pipeline agents.

In this latest update, there are definitely some companies we have been following longitudinally who are either poised for future success and growth… or due for a correction if the promising science doesn’t pan out as expected in the clinic.

Indeed one of those companies has already hit success and disappointment in the last two months alone, such is the roller coaster that is oncology R&D.

Please note that this is a rolling blog, which means that numerous updates are added throughout the day as new information becomes available.

To learn more from our oncology coverage and get a heads up on our latest commentary JPM annual meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

After writing about how the design aspects of antibodies can affect clinical performance recently, a few fascinated readers wrote in asking if there were more examples they could learn from.

Sure there are, and so that simple question inspired five more examples.

They range from small to large biotech/pharma, both public and private – no one has dominance in innovation chops, after all.

In this latest review we look at examples from CAR-T cell therapies, antibodies, immunocytokines and even bispecifics – there’s a lot of cool science going under the hood that many casual observers simply do not realise.

What’s more, some of the selected improvements and changes may (or may not) lead to enhancement of clinical performance down the road, so it is important to pay attention to what’s going on relative to each niche rather than be surprised and caught unaware…

To learn more and get a heads up on our latest oncology insights and R&D analysis, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

San Francisco JPM16 Day 2It’s Tuesday at the 2016 JP Morgan Healthcare conference in San Francisco (Twitter #JPM16).

Each day of #JPM16 we’re doing a rolling blog post which we’re updating throughout the day with commentary and insights on the company presentations we’re covering.

While we’re not giving a blow-by-blow account, many companies have the slides readily available, we will be commenting on noteworthy news, and what we learn about corporate strategy going into 2016.

For those of you who like to catch up with the final summary of each day’s highlights, you can read yesterday’s Day 1 synopsis here and our interview with Seattle Genetics CEO, Clay Siegall here.

Subscribers can login or you can purchase access.

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!